

Mary M Machulda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9495849/publications.pdf>

Version: 2024-02-01

194
papers

10,736
citations

31976

53
h-index

40979

93
g-index

195
all docs

195
docs citations

195
times ranked

10602
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 441-451.	1.8	1
2	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 602-611.	0.8	20
3	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. <i>Alzheimer's and Dementia</i> , 2022, 18, 1128-1140.	0.8	88
4	Autopsy Validation of Progressive Supranuclear Palsyâ€Predominant Speech/Language Disorder Criteria. <i>Movement Disorders</i> , 2022, 37, 213-218.	3.9	6
5	Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 491-498.	2.6	8
6	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	3.1	9
7	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	5.2	14
8	OUP accepted manuscript. <i>Archives of Clinical Neuropsychology</i> , 2022, , .	0.5	1
9	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. <i>NeuroImage: Clinical</i> , 2022, 34, 102999.	2.7	11
10	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. <i>Journal of Neurology</i> , 2022, 269, 4110-4128.	3.6	7
11	Posterior cortical atrophy: Primary occipital variant. <i>European Journal of Neurology</i> , 2022, 29, 2138-2143.	3.3	7
12	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. <i>NeuroImage</i> , 2022, 251, 119020.	4.2	9
13	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2022, 37, 702-712.	3.9	14
14	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	7.7	3
15	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.1	12
16	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. <i>Brain Communications</i> , 2022, 4, .	3.3	5
17	Cross-Sectional and Longitudinal Assessment of Behavior in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 193-202.	1.5	1
18	Artificial Intelligenceâ€Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. <i>Mayo Clinic Proceedings</i> , 2022, 97, 871-880.	3.0	6

#	ARTICLE	IF	CITATIONS
19	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 179-191.	1.2	25
20	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 1693-1706.	2.9	44
21	Association of Initial β -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	9.0	27
22	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. <i>Annals of Neurology</i> , 2021, 89, 520-533.	5.3	21
23	Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 377-388.	2.6	12
24	Association of Cortical and Subcortical β -Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 64-71.	1.8	9
25	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30-91 Years and the Importance of Adjusting for Sex. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 211-226.	1.8	33
26	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 17-28.	1.5	5
27	Phonological Errors in Posterior Cortical Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 195-203.	1.5	8
28	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 48.	5.2	18
29	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. <i>Neurocase</i> , 2021, 27, 212-222.	0.6	4
30	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. <i>Journal of Neurology</i> , 2021, 268, 3409-3420.	3.6	12
31	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 683-693.	2.6	7
32	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1362-1369.	2.7	16
33	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.8	16
34	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. <i>Brain Communications</i> , 2021, 3, fcab076.	3.3	13
35	<sc>NIA's Alzheimer's Disease Framework: Clinical Characterization of Stages. <i>Annals of Neurology</i> , 2021, 89, 1145-1156.	5.3	31
36	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. <i>Brain Communications</i> , 2021, 3, fcab106.	3.3	38

#	ARTICLE	IF	CITATIONS
37	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphereâ€Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , 2021, 97, e523-e534.	1.1	4
38	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. <i>Nature Communications</i> , 2021, 12, 3452.	12.8	34
39	Neurodegeneration of the visual word form area in a patient with word form alexia. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 359-360.	0.4	5
40	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. <i>German Journal of Exercise and Sport Research</i> , 2021, 51, 487-494.	1.2	5
41	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	3.3	12
42	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimerâ€™s Disease Based on Cogstate One Card Learning Accuracy Performance. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 861-877.	2.6	7
43	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 108, 90-98.	3.1	11
44	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. <i>Brain Communications</i> , 2021, 3, fcaa238.	3.3	11
45	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. <i>Neurology: Clinical Practice</i> , 2021, 11, 249-255.	1.6	9
46	Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment. <i>JAMA Network Open</i> , 2021, 4, e2131448.	5.9	26
47	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 199.	6.2	32
48	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , 2020, 124, 33-43.	2.4	5
49	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. <i>Neurology</i> , 2020, 94, e15-e29.	1.1	25
50	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 34-40.	2.2	20
51	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. <i>Neurobiology of Aging</i> , 2020, 96, 176-183.	3.1	27
52	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. <i>Neurocase</i> , 2020, 26, 259-263.	0.6	6
53	Longitudinal Amyloid- β^2 PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 377-389.	2.6	7
54	Expanded genetic insight and clinical experience of DNMT1-complex disorder. <i>Neurology: Genetics</i> , 2020, 6, e456.	1.9	7

#	ARTICLE	IF	CITATIONS
55	Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 911-917.	2.6	3
56	Automated Hippocampal Subfield Volumetric Analyses in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 927-937.	2.6	14
57	Sensitivity and Specificity of Tau and Amyloid β^2 Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	5.3	32
58	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2020, 16, 1013-1022.	0.8	20
59	Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. <i>Journal of Neurology</i> , 2020, 267, 2603-2611.	3.6	12
60	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	3.3	81
61	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	7.6	51
62	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 261-274.	2.6	25
63	Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in <i>PRNP</i> : the next generation. <i>Neurocase</i> , 2020, 26, 211-219.	0.6	4
64	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. <i>Neurology</i> , 2020, 94, e1571-e1579.	1.1	18
65	Medical Doctors and Dementia: A Longitudinal Study. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1250-1255.	2.6	0
66	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	5.3	17
67	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	3.7	17
68	Brain amyloid, cortical thickness, and changes in activities of daily living. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 474-485.	3.7	3
69	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. <i>Brain and Language</i> , 2020, 204, 104773.	1.6	15
70	Pick's disease: clinicopathologic characterization of 21 cases. <i>Journal of Neurology</i> , 2020, 267, 2697-2704.	3.6	17
71	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2020, 93, 52-54.	3.1	1
72	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.1	13

#	ARTICLE	IF	CITATIONS
73	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 1618-1631.	3.6	53
74	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 877-883.	3.6	16
75	Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE ϵ 4 genotype status: the Mayo Clinic Study of Aging. <i>European Journal of Ageing</i> , 2019, 16, 491-502.	2.8	9
76	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. <i>Brain and Language</i> , 2019, 197, 104676.	1.6	29
77	Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia. <i>Age and Ageing</i> , 2019, 48, 888-894.	1.6	13
78	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	9.0	182
79	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1516-1523.	3.0	35
80	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <i>Annals of Neurology</i> , 2019, 86, 866-877.	5.3	40
81	Comparison of variables associated with cerebrospinal fluid neurofilament, total τ , and neurogranin. <i>Alzheimer's and Dementia</i> , 2019, 15, 1437-1447.	0.8	38
82	The bivariate distribution of amyloid- β 2 and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	7.6	129
83	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. <i>Stroke</i> , 2019, 50, 3037-3044.	2.0	39
84	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	7.6	33
85	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	7.4	223
86	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 878-887.	0.8	41
87	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.1	62
88	Plasma and CSF neurofilament light. <i>Neurology</i> , 2019, 93, e252-e260.	1.1	160
89	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101823.	2.7	54
90	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. <i>Brain</i> , 2019, 142, 1134-1147.	7.6	72

#	ARTICLE	IF	CITATIONS
91	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 675-685.	0.8	36
92	Cortical β -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. <i>Translational Psychiatry</i> , 2019, 9, 123.	4.8	54
93	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2019, 79, 43-49.	3.1	7
94	Prominent auditory deficits in primary progressive aphasia: A case study. <i>Cortex</i> , 2019, 117, 396-406.	2.4	14
95	Entorhinal cortex tau, amyloid- β , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	7.6	68
96	Quantity and quality of mental activities and the risk of incident mild cognitive impairment. <i>Neurology</i> , 2019, 93, e548-e558.	1.1	38
97	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.1	19
98	The influence of β -amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.1	10
99	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , 2019, 85, 155-160.	5.3	32
100	Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests. <i>Clinical Neuropsychologist</i> , 2019, 33, 1102-1126.	2.3	13
101	Electroencephalography in primary progressive aphasia and apraxia of speech. <i>Aphasiology</i> , 2019, 33, 1410-1417.	2.2	9
102	The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNF α and Cognitive Outcomes in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1289-1295.	3.6	42
103	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 355.	3.4	25
104	The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2018, 66, 68-74.	3.1	30
105	Joint associations of β -amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	3.1	27
106	Plasma phospho-tau ¹⁸¹ increases with Alzheimer's disease clinical severity and is associated with tau and amyloid- β positron emission tomography. <i>Alzheimer's and Dementia</i> , 2018, 14, 989-997.	0.8	386
107	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1713-1724.	2.6	45
108	[¹⁸ F]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611. 5.3	5.3	73

#	ARTICLE	IF	CITATIONS
109	Tau-PET imaging with [¹⁸ F]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	2.4	42
110	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.1	24
111	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. <i>Neurology</i> , 2018, 90, e466-e473.	1.1	55
112	[¹⁸ F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	5.3	67
113	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. <i>Brain</i> , 2018, 141, 302-317.	7.6	42
114	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	7.6	218
115	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <i>JAMA Neurology</i> , 2018, 75, 970.	9.0	116
116	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.8	80
117	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	7.6	309
118	Disrupted functional connectivity in primary progressive apraxia of speech. <i>NeuroImage: Clinical</i> , 2018, 18, 617-629.	2.7	36
119	Molecular neuroimaging in primary progressive aphasia with predominant agraphia. <i>Neurocase</i> , 2018, 24, 121-123.	0.6	2
120	Association of Excessive Daytime Sleepiness With Longitudinal ¹²⁵ I-Amyloid Accumulation in Elderly Persons Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 672.	9.0	150
121	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	3.0	34
122	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2274-2281.	2.6	10
123	Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon?. <i>Journal of the Acoustical Society of America</i> , 2018, 144, 3364-3370.	1.1	5
124	Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech. <i>American Journal of Speech-Language Pathology</i> , 2018, 27, 1303-1318.	1.8	36
125	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. <i>Annals of Neurology</i> , 2018, 84, 705-716.	5.3	49
126	Quantitative assessment of grammar in amyloid-negative logopenic aphasia. <i>Brain and Language</i> , 2018, 186, 26-31.	1.6	7

#	ARTICLE	IF	CITATIONS
127	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 281-290.	2.6	22
128	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	1.6	106
129	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , 2018, 390, 246-254.	0.6	4
130	Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1114-1120.	2.7	25
131	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. <i>Neurocase</i> , 2018, 24, 111-120.	0.6	25
132	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	7.7	125
133	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <i>JAMA Neurology</i> , 2017, 74, 718.	9.0	107
134	Age-specific and sex-specific prevalence of cerebral β -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	10.2	241
135	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. <i>Annals of Neurology</i> , 2017, 81, 871-882.	5.3	51
136	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 21-30.	2.4	86
137	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. <i>Neurology</i> , 2017, 89, 2271-2279.	1.1	30
138	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. <i>Annals of Neurology</i> , 2017, 82, 706-718.	5.3	136
139	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , 2017, 89, 2039-2048.	1.1	15
140	Neurocognition in individuals with incidentally-identified meningioma. <i>Journal of Neuro-Oncology</i> , 2017, 134, 125-132.	2.9	25
141	Decreased Glutamate Levels in Patients with Amnesic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. <i>Journal of Neuroimaging</i> , 2017, 27, 630-636.	2.0	29
142	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. <i>JAMA Neurology</i> , 2017, 74, 1073.	9.0	149
143	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. <i>Clinical Neuropsychologist</i> , 2017, 31, 99-117.	2.3	47
144	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. <i>Sleep Medicine</i> , 2017, 32, 236-243.	1.6	79

#	ARTICLE	IF	CITATIONS
145	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. <i>Alzheimer's and Dementia</i> , 2017, 13, 168-177.	0.8	110
146	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.8	581
147	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. <i>Cortex</i> , 2017, 90, 138-148.	2.4	22
148	¹ H-MRS metabolites and rate of β -amyloid accumulation on serial PET in clinically normal adults. <i>Neurology</i> , 2017, 89, 1391-1399.	1.1	18
149	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. <i>Neurology: Genetics</i> , 2017, 3, e201.	1.9	2
150	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1609-1616.	2.6	35
151	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1019-1029.	2.6	24
152	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. <i>Neurology</i> , 2016, 86, 2077-2084.	1.1	27
153	Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 559-567.	2.6	79
154	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.1	22
155	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	3.1	20
156	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 1226-1234.	0.8	107
157	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , 2016, 15, 56-64.	10.2	104
158	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. <i>NeuroImage: Clinical</i> , 2016, 11, 90-98.	2.7	10
159	Effect of intellectual enrichment on AD biomarker trajectories. <i>Neurology</i> , 2016, 86, 1128-1135.	1.1	71
160	Decline in Weight and Incident Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2016, 73, 439.	9.0	89
161	Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 281-291.	0.8	45
162	Association Between Olfactory Dysfunction and Amnesic Mild Cognitive Impairment and Alzheimer Disease Dementia. <i>JAMA Neurology</i> , 2016, 73, 93.	9.0	294

#	ARTICLE	IF	CITATIONS
163	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. <i>JAMA Neurology</i> , 2016, 73, 85.	9.0	160
164	Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 429-435.	1.8	78
165	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	2.6	27
166	Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 167-176.	2.6	23
167	Retrospective Analysis of Interobserver Spatial Variability in the Localization of Broca's and Wernicke's Areas Using Three Different fMRI Language Paradigms. <i>Journal of Neuroimaging</i> , 2015, 25, 626-633.	2.0	6
168	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. <i>Brain and Language</i> , 2015, 142, 45-53.	1.6	49
169	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	2.6	19
170	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2015, 36, 1245-1252.	3.1	83
171	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , 2015, 69, 220-236.	2.4	133
172	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. <i>Journal of Neurology</i> , 2015, 262, 2064-2072.	3.6	10
173	Neuropsychiatric symptoms, <i>APOE</i> ϵ 4, and the risk of incident dementia. <i>Neurology</i> , 2015, 84, 935-943.	1.1	101
174	Risk and protective factors for cognitive impairment in persons aged 85 years and older. <i>Neurology</i> , 2015, 84, 1854-1861.	1.1	61
175	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	7.6	222
176	Age, Sex, and <i>APOE</i> ϵ 4 Effects on Memory, Brain Structure, and β -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	9.0	305
177	Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. <i>Alzheimer's and Dementia</i> , 2015, 11, 1367-1376.	0.8	85
178	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	7.6	170
179	Multimorbidity and Risk of Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1783-1790.	2.6	135
180	Role of β -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	9.0	23

#	ARTICLE	IF	CITATIONS
181	Spectrum of cognition short of dementia. <i>Neurology</i> , 2015, 85, 1712-1721.	1.1	67
182	Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 60-67.	3.1	90
183	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	9.0	57
184	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. <i>JAMA Neurology</i> , 2014, 71, 1017.	9.0	160
185	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2014, 10, 62-66.	0.8	14
186	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , 2014, 10, 779-789.	0.8	26
187	<i>APOE</i> ϵ 4 influences β -amyloid deposition in primary progressive aphasia and speech apraxia. <i>Alzheimer's and Dementia</i> , 2014, 10, 630-636.	0.8	31
188	The evolution of primary progressive apraxia of speech. <i>Brain</i> , 2014, 137, 2783-2795.	7.6	134
189	Identification of an atypical variant of logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 139-144.	1.6	49
190	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. <i>Neurology</i> , 2013, 81, 337-345.	1.1	142
191	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. <i>Clinical Neuropsychologist</i> , 2013, 27, 1247-1264.	2.3	124
192	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. <i>Brain</i> , 2012, 135, 1522-1536.	7.6	325
193	Effect of <i>APOE</i> ϵ 4 Status on Intrinsic Network Connectivity in Cognitively Normal Elderly Subjects. <i>Archives of Neurology</i> , 2011, 68, 1131.	4.5	197
194	Functional magnetic resonance imaging changes in amnesic and nonamnesic mild cognitive impairment during encoding and recognition tasks. <i>Journal of the International Neuropsychological Society</i> , 2009, 15, 372-382.	1.8	73